A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: ER+ / HER2- Advanced Breast Cancer
Interventions: DRUG: SHR6390、Famitinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.